(KIDS) Orthopediatrics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 398m USD | Total Return: -23.9% in 12m

Implants, Instruments, Scoliosis, Trauma, Braces
Total Rating 19
Safety 43
Buy Signal -0.59
Medical Devices
Industry Rotation: -4.0
Market Cap: 398M
Avg Turnover: 2.58M USD
ATR: 4.79%
Peers RS (IBD): 22.9
Risk 5d forecast
Volatility47.0%
Rel. Tail Risk-6.01%
Reward TTM
Sharpe Ratio-0.70
Alpha-64.00
Character TTM
Beta0.969
Beta Downside1.096
Drawdowns 3y
Max DD70.76%
CAGR/Max DD-0.44
EPS (Earnings per Share) EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2021-03": -0.47, "2021-06": -0.19, "2021-09": -0.11, "2021-12": -0.24, "2022-03": -0.47, "2022-06": -0.02, "2022-09": -0.07, "2022-12": -0.35, "2023-03": -0.3, "2023-06": -0.13, "2023-09": -0.2, "2023-12": -0.29, "2024-03": -0.34, "2024-06": -0.26, "2024-09": -0.34, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24, "2025-12": -0.26,
EPS CAGR: 77.70%
EPS Trend: -10.8%
Last SUE: 0.37
Qual. Beats: 0
Revenue Revenue of KIDS over the last years for every Quarter: 2021-03: 21.462, 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25, 2025-12: 61.605,
Rev. CAGR: 29.43%
Rev. Trend: 94.6%
Last SUE: 0.27
Qual. Beats: 0

Warnings

Interest Coverage Ratio -4.9 is critical

Altman Z'' -1.11 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: KIDS Orthopediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) designs, develops, and markets a full suite of pediatric-specific orthopedic implants, instruments, and braces-including trauma fixation systems, scoliosis correction devices, and sports-medicine solutions-serving surgeons and caregivers in the United States and abroad.

In its most recent quarter (Q4 2023), the company reported revenue of $45.2 million, up 12 % year-over-year, while maintaining a cash position of roughly $45 million, underscoring a solid liquidity base despite a modest net loss of $3.1 million.

The pediatric orthopedic market is projected to grow at a compound annual growth rate of about 6 % through 2028, driven by rising rates of childhood fractures, expanding sports participation, and broader insurance reimbursement for minimally invasive procedures.

For a deeper dive, you might explore ValueRay’s detailed analysis of KIDS to complement your own research.

Headlines to Watch Out For
  • Pediatric orthopedic surgery volume directly impacts device sales
  • New product launches expand market share and revenue
  • Regulatory approvals for devices influence market access
  • Healthcare reimbursement policies affect product adoption
  • Competition from larger medical device companies pressures pricing
Piotroski VR‑10 (Strict) 1.5
Net Income: -39.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 5.75 > 1.0
NWC/Revenue: 88.95% < 20% (prev 99.26%; Δ -10.31% < -1%)
CFO/TA -0.01 > 3% & CFO -4.85m > Net Income -39.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.55 > 1.5 & < 3
Outstanding Shares: last quarter (23.6m) vs 12m ago 1.74% < -2%
Gross Margin: 73.05% > 18% (prev 0.73%; Δ 7.23k% > 0.5%)
Asset Turnover: 47.45% > 50% (prev 43.26%; Δ 4.18% > 0%)
Interest Coverage Ratio: -4.86 > 6 (EBITDA TTM -7.88m / Interest Expense TTM 6.00m)
Altman Z'' -1.11
A: 0.40 (Total Current Assets 256.4m - Total Current Liabilities 46.2m) / Total Assets 523.1m
B: -0.53 (Retained Earnings -275.2m / Total Assets 523.1m)
C: -0.06 (EBIT TTM -29.1m / Avg Total Assets 498.1m)
D: -1.56 (Book Value of Equity -275.7m / Total Liabilities 176.5m)
Altman-Z'' Score: -1.11 = CCC
Beneish M -2.84
DSRI: 1.10 (Receivables 53.8m/42.4m, Revenue 236.3m/204.7m)
GMI: 0.99 (GM 73.05% / 72.58%)
AQI: 1.11 (AQ_t 0.42 / AQ_t-1 0.37)
SGI: 1.15 (Revenue 236.3m / 204.7m)
TATA: -0.07 (NI -39.6m - CFO -4.85m) / TA 523.1m)
Beneish M-Score: -2.84 (Cap -4..+1) = A
What is the price of KIDS shares? As of April 13, 2026, the stock is trading at USD 15.97 with a total of 146,545 shares traded.
Over the past week, the price has changed by +0.19%, over one month by -8.95%, over three months by -20.59% and over the past year by -23.88%.
Is KIDS a buy, sell or hold? Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.
  • StrongBuy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the KIDS price?
Analysts Target Price 24.9 55.9%
Orthopediatrics (KIDS) - Fundamental Data Overview as of 09 April 2026
P/S = 1.6856
P/B = 1.1691
Revenue TTM = 236.3m USD
EBIT TTM = -29.1m USD
EBITDA TTM = -7.88m USD
Long Term Debt = 99.8m USD (from longTermDebt, last quarter)
Short Term Debt = 170k USD (from shortTermDebt, last quarter)
Debt = 100.0m USD (corrected: LT Debt 99.8m + ST Debt 170k)
Net Debt = 28.8m USD (from netDebt column, last quarter)
Enterprise Value = 437.5m USD (398.4m + Debt 100.0m - CCE 60.9m)
Interest Coverage Ratio = -4.86 (Ebit TTM -29.1m / Interest Expense TTM 6.00m)
EV/FCF = -27.41x (Enterprise Value 437.5m / FCF TTM -16.0m)
FCF Yield = -3.65% (FCF TTM -16.0m / Enterprise Value 437.5m)
FCF Margin = -6.75% (FCF TTM -16.0m / Revenue TTM 236.3m)
Net Margin = -16.78% (Net Income TTM -39.6m / Revenue TTM 236.3m)
Gross Margin = 73.05% ((Revenue TTM 236.3m - Cost of Revenue TTM 63.7m) / Revenue TTM)
Gross Margin QoQ = 73.22% (prev 73.92%)
Tobins Q-Ratio = 0.84 (Enterprise Value 437.5m / Total Assets 523.1m)
Interest Expense / Debt = 1.93% (Interest Expense 1.93m / Debt 100.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.0m (EBIT -29.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.55 (Total Current Assets 256.4m / Total Current Liabilities 46.2m)
Debt / Equity = 0.29 (Debt 100.0m / totalStockholderEquity, last quarter 346.6m)
 Debt / EBITDA = -3.66 (negative EBITDA) (Net Debt 28.8m / EBITDA -7.88m)
 Debt / FCF = -1.80 (negative FCF - burning cash) (Net Debt 28.8m / FCF TTM -16.0m)
 Total Stockholder Equity = 349.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.96% (Net Income -39.6m / Total Assets 523.1m)
RoE = -11.34% (Net Income TTM -39.6m / Total Stockholder Equity 349.6m)
RoCE = -6.48% (EBIT -29.1m / Capital Employed (Equity 349.6m + L.T.Debt 99.8m))
 RoIC = -5.21% (negative operating profit) (NOPAT -23.0m / Invested Capital 442.1m)
 WACC = 7.81% (E(398.4m)/V(498.4m) * Re(9.39%) + D(100.0m)/V(498.4m) * Rd(1.93%) * (1-Tc(0.21)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.77%
 [DCF] Fair Price = unknown (Cash Flow -16.0m)
 EPS Correlation: -10.85 | EPS CAGR: 77.70% | SUE: 0.37 | # QB: 0
Revenue Correlation: 94.55 | Revenue CAGR: 29.43% | SUE: 0.27 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.28 | Chg7d=-0.003 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-12-31): EPS=-1.07 | Chg7d=-0.027 | Chg30d=-0.027 | Revisions Net=+1 | Growth EPS=-6.8% | Growth Revenue=+11.8%
EPS next Year (2027-12-31): EPS=-0.69 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+1 | Growth EPS=+34.9% | Growth Revenue=+11.9%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle